Diabetes and Bone Health: Latest Evidence and Clinical Implications

Overview

Journal Ther Adv Musculoskelet Dis

Date 2017 Mar 28

PMID 28344668

Citations 40

Authors

Vikram Sundararaghavan

Matthew M Mazur

Brad Evans

Jiayong Liu

Nabil A Ebraheim

Affiliations

Soon will be listed here.

Abstract

As the prevalence of diabetes is increasing worldwide, research on some of the lesser-known effects, including impaired bone health, are gaining a lot of attention. The two most common forms of diabetes are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). These two differ in their physiology, with T1DM stemming from an inability to produce insulin, and T2DM involving an insufficient response to the insulin that is produced. This review aims to highlight the most current information regarding diabetes as it relates to bone health. It looks at biochemical changes that characterize diabetic bone; notably increased adiposity, altered bone metabolism, and variations in bone mineral density (BMD). Then several hypotheses are analyzed, concerning how these changes may be detrimental to the highly orchestrated processes that are involved in bone formation and turnover, and ultimately result in the distinguishing features of diabetic bone. The review proceeds by explaining the effects of antidiabetes medications on bone health, then highlighting several ways that diabetes can play a part in other clinical treatment outcomes. With diabetes negatively affecting bone health and creating other clinical problems, and its treatment options potentiating these effects, physicians should consider the use of anti-osteoporotic drugs to supplement standard anti-diabetes medications in patients suffering with diabetic bone loss.

Citing Articles

Effect of Fibroblast Growth Factor (FGF) 19 and 21 on Hip Geometry and Strength in Post-menopausal Osteoporosis (PMO).

Kim E, Moore A, Dulnoan D, Hampson G Calcif Tissue Int. 2024; 115(5):562-569.

PMID: 39341924 PMC: 11531423. DOI: 10.1007/s00223-024-01284-3.

Bone microarchitecture and strength assessed by HRpQCT in individuals with type 2 diabetes and prediabetes: the Maastricht study.

van Hulten V, Sarodnik C, Driessen J, Viggers R, Rasmussen N, Geusens P JBMR Plus. 2024; 8(9):ziae086.

PMID: 39108361 PMC: 11299510. DOI: 10.1093/jbmrpl/ziae086.

The single point insulin sensitivity estimator (SPISE) is associated with bone health in Arab adults.

Al-Daghri N, Wani K, Khattak M, Alnaami A, Al-Saleh Y, Sabico S Aging Clin Exp Res. 2024; 36(1):136.

PMID: 38904881 PMC: 11192813. DOI: 10.1007/s40520-024-02789-5.

Effects of metabolic syndrome on bone mineral density in postmenopausal Turkish women.

Bahtiyarca Z, Serce A Afr Health Sci. 2024; 23(3):99-108.

PMID: 38357185 PMC: 10862646. DOI: 10.4314/ahs.v23i3.13.

Plasma undercarboxylated osteocalcin dynamics with glycemic stress reflects insulin sensitivity and beta-cell function in humans with and without T2DM.

Fuller K, Bohne E, Mey J, Blackburn B, Miranda V, Varady K Metabol Open. 2023; 20:100264.

PMID: 38115864 PMC: 10728569. DOI: 10.1016/j.metop.2023.100264.

References

Wukich D, Lowery N, McMillen R, Frykberg R . Postoperative infection rates in foot and ankle surgery: a comparison of patients with and without diabetes mellitus. J Bone Joint Surg Am. 2010; 92(2):287-95. DOI: 10.2106/JBJS.I.00080. View

Poon C, Li R, Seto S, Kong S, Ho H, Hoi M . In vitro vitamin K(2) and 1α,25-dihydroxyvitamin D(3) combination enhances osteoblasts anabolism of diabetic mice. Eur J Pharmacol. 2015; 767:30-40. DOI: 10.1016/j.ejphar.2015.09.048. View

Botolin S, Faugere M, Malluche H, Orth M, Meyer R, McCabe L . Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology. 2005; 146(8):3622-31. PMC: 1242186. DOI: 10.1210/en.2004-1677. View

Ikeda T, Manabe H, Iwata K . Clinical significance of alendronate in postmenopausal type 2 diabetes mellitus. Diabetes Metab. 2004; 30(4):355-8. DOI: 10.1016/s1262-3636(07)70128-3. View

Zhao G, Monier-Faugere M, Langub M, Geng Z, Nakayama T, Pike J . Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000; 141(7):2674-82. DOI: 10.1210/endo.141.7.7585. View

Iorio R, Williams K, Marcantonio A, Specht L, Tilzey J, Healy W . Diabetes mellitus, hemoglobin A1C, and the incidence of total joint arthroplasty infection. J Arthroplasty. 2011; 27(5):726-9.e1. DOI: 10.1016/j.arth.2011.09.013. View

Kayal R, Tsatsas D, Bauer M, Allen B, Al-Sebaei M, Kakar S . Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res. 2007; 22(4):560-8. PMC: 3109431. DOI: 10.1359/jbmr.070115. View

Campbell J, Drucker D . Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013; 17(6):819-837. DOI: 10.1016/j.cmet.2013.04.008. View

Colditz G, Willett W, Rotnitzky A, Manson J . Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995; 122(7):481-6. DOI: 10.7326/0003-4819-122-7-199504010-00001. View

10.

Piccinin M, Khan Z . Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications. Adipocyte. 2015; 3(4):263-72. PMC: 4550679. DOI: 10.4161/adip.32215. View

11.

Haas B, Eckstein N, Pfeifer V, Mayer P, Hass M . Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes. 2014; 4:e143. PMC: 4259905. DOI: 10.1038/nutd.2014.40. View

12.

Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F . Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2011; 122(6):253-70. PMC: 3398862. DOI: 10.1042/CS20110386. View

13.

Santana R, Xu L, Chase H, Amar S, Graves D, Trackman P . A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes. 2003; 52(6):1502-10. DOI: 10.2337/diabetes.52.6.1502. View

14.

Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W . Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care. 2005; 28(12):2850-5. DOI: 10.2337/diacare.28.12.2850. View

15.

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley R . Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86(5):1930-5. DOI: 10.1210/jcem.86.5.7463. View

16.

Akin O, Gol K, Akturk M, Erkaya S . Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Gynecol Endocrinol. 2003; 17(1):19-29. View

17.

Hoffmann B, El-Mansy M, Sem D, Greene A . Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity. J Med Chem. 2012; 55(19):8260-71. PMC: 4113394. DOI: 10.1021/jm301204r. View

18.

Jamsen E, Nevalainen P, Eskelinen A, Huotari K, Kalliovalkama J, Moilanen T . Obesity, diabetes, and preoperative hyperglycemia as predictors of periprosthetic joint infection: a single-center analysis of 7181 primary hip and knee replacements for osteoarthritis. J Bone Joint Surg Am. 2012; 94(14):e101. DOI: 10.2106/JBJS.J.01935. View

19.

Zhou Z, Immel D, Xi C, Bierhaus A, Feng X, Mei L . Regulation of osteoclast function and bone mass by RAGE. J Exp Med. 2006; 203(4):1067-80. PMC: 2118287. DOI: 10.1084/jem.20051947. View

20.

Lu H, Kraut D, Gerstenfeld L, Graves D . Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology. 2002; 144(1):346-52. DOI: 10.1210/en.2002-220072. View